- Home
- EDSA vs CDT Comparison
EDSA vs CDT Comparison
Compare EDSA & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDSA
- CDT
- Stock Information
- Founded
- EDSA 2015
- CDT 2019
- Country
- EDSA Canada
- CDT United States
- Employees
- EDSA N/A
- CDT N/A
- Industry
- EDSA Biotechnology: Pharmaceutical Preparations
- CDT Biotechnology: Pharmaceutical Preparations
- Sector
- EDSA Health Care
- CDT Health Care
- Exchange
- EDSA Nasdaq
- CDT Nasdaq
- Market Cap
- EDSA 6.2M
- CDT 5.3M
- IPO Year
- EDSA N/A
- CDT N/A
- Fundamental
- Price
- EDSA $2.03
- CDT $0.39
- Analyst Decision
- EDSA Strong Buy
- CDT
- Analyst Count
- EDSA 1
- CDT 0
- Target Price
- EDSA $21.00
- CDT N/A
- AVG Volume (30 Days)
- EDSA 14.5K
- CDT 768.1K
- Earning Date
- EDSA 05-14-2025
- CDT 05-15-2025
- Dividend Yield
- EDSA N/A
- CDT N/A
- EPS Growth
- EDSA N/A
- CDT N/A
- EPS
- EDSA N/A
- CDT N/A
- Revenue
- EDSA N/A
- CDT N/A
- Revenue This Year
- EDSA N/A
- CDT N/A
- Revenue Next Year
- EDSA N/A
- CDT N/A
- P/E Ratio
- EDSA N/A
- CDT N/A
- Revenue Growth
- EDSA N/A
- CDT N/A
- 52 Week Low
- EDSA $1.55
- CDT $0.51
- 52 Week High
- EDSA $5.59
- CDT $350.00
- Technical
- Relative Strength Index (RSI)
- EDSA 36.85
- CDT 31.63
- Support Level
- EDSA $1.99
- CDT $0.38
- Resistance Level
- EDSA $2.14
- CDT $0.41
- Average True Range (ATR)
- EDSA 0.11
- CDT 0.04
- MACD
- EDSA -0.03
- CDT 0.01
- Stochastic Oscillator
- EDSA 21.28
- CDT 9.89
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
About CDT Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.